**Core Concept:** Crohn's Disease is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. Inflammatory symptoms can include abdominal pain, diarrhea, and weight loss. Inflammatory bowel disease therapies aim to reduce inflammation and alleviate symptoms.

**Why the Correct Answer is Right:** The correct answer (D) is based on the patient's reported intolerance to oral steroid therapy with budesonide. Given the patient's adverse reaction to budesonide, it is not a suitable choice for continuing treatment. Mesalamine derivatives like Pentasa are used for Crohn's Disease management, targeting inflammation and mucosal healing. However, they do not adequately address the systemic inflammation that may occur in severe cases like this patient's recent disease flare-up.

**Why Each Wrong Option is Incorrect:**

A. Oral corticosteroids (e.g., budesonide) are a common treatment for Crohn's Disease due to their potent anti-inflammatory effects. However, the patient has already experienced intolerance to budesonide, so this option is incorrect.

B. Although aminosalicylates like mesalamine can reduce inflammation in Crohn's Disease, they are less effective than corticosteroids in severe cases. In this patient's recent flare-up, a more potent therapy is needed.

C. Immunosuppressants like azathioprine or methotrexate are generally prescribed for patients unable to tolerate corticosteroids. In this situation, the patient has already demonstrated intolerance to corticosteroids, making this option inappropriate.

D. Enteral nutrition, or tube feeding, is an option for patients with severe malabsorption due to Crohn's Disease. However, the patient has an active flare-up, so this option is not directly addressing the primary issue.

E. Biologic agents like infliximab or adalimumab are used in patients with moderate to severe Crohn's Disease and intolerance to conventional therapies. Given the patient's recent flare-up and intolerance to corticosteroids, these biologic agents are not immediately appropriate.

F. Corticosteroids, like prednisolone, are another immunosuppressive therapy with anti-inflammatory properties. As the patient has demonstrated intolerance to corticosteroids, this therapy is not suitable.

**Clinical Pearls:**

In patients with Crohn's Disease and intolerance to corticosteroids, biologic agents like infliximab or adalimumab should be considered after a suitable trial of an immunosuppressive therapy, such as azathioprine or methotrexate, and a trial of a mesalamine derivative like Pentasa has been attempted. This case highlights the importance of considering the patient's medical history and trial of other therapies before moving on to more potent immunosuppressive options.